MedTrace Logo

Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)

NCT04066660 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2025-01-13

No results posted yet for this study

Summary

A randomized, double-blind, controlled trial was conducted evaluating the efficacy of Oligo-Fucoidan with the molecular weight ranged from 500 to 800 Da. as a supplemental therapy in patients with advanced hepatocellular carcinoma. The previous study results demonstrate the advantages of Oligo-Fucoidan in improving the disease control rate in metastatic colorectal cancer. The previous study might provide insights into the development of cancer treatments, particularly in the combination of natural or herbal products with chemotarget agents.

Conditions

Interventions

DIETARY_SUPPLEMENT

Oligo Fucoidan

4.4 g oligo fucoidan powder, oral, BID

DIETARY_SUPPLEMENT

Placebo

4.4 g placebo powder, oral, BID

Sponsors & Collaborators

  • Hi-Q Marine Biotech International, Ltd.

    lead INDUSTRY

Principal Investigators

  • Xizhong Shen, PhD · Shanghai Zhongshan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2024-06-30
Completion
2024-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04066660 on ClinicalTrials.gov